Symbols / LSTA $5.03 -0.10%
LSTA Chart
About
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 44.32M |
| Enterprise Value | 25.12M | Income | -18.24M | Sales | 1.07M |
| Book/sh | 1.98 | Cash/sh | 2.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 26 | IPO | — |
| P/E | — | Forward P/E | -4.90 | PEG | — |
| P/S | 41.42 | P/B | 2.53 | P/C | — |
| EV/EBITDA | -1.26 | EV/Sales | 23.47 | Quick Ratio | 4.42 |
| Current Ratio | 4.72 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.13 | EPS next Y | -1.02 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -41.86% |
| ROE | -72.17% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -18.77% | Profit Margin | 0.00% | Shs Outstand | 8.82M |
| Shs Float | 7.06M | Short Float | 0.41% | Short Ratio | 0.09 |
| Short Interest | — | 52W High | 5.07 | 52W Low | 1.81 |
| Beta | 1.27 | Avg Volume | 172.74K | Volume | 56.63K |
| Target Price | $11.33 | Recom | None | Prev Close | $5.03 |
| Price | $5.03 | Change | -0.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.33
Mean price target
2. Current target
$5.03
Latest analyst target
3. DCF / Fair value
$-23.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.03
Low
$4.00
High
$15.00
Mean
$11.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | down | Brookline Capital | Buy → Hold | — |
| 2025-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-07-15 | main | Brookline Capital | Buy → Buy | $32 |
| 2024-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-19 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-04-26 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-04-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-03-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-01-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-05-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-03-31 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2022-10-19 | main | HC Wainwright & Co. | — → Buy | $15 |
- Lisata investors offered $5 cash now, $1 more if certepetide gets filed - Stock Titan Fri, 06 Mar 2026 23
- Lisata Therapeutics to Be Acquired by Kuva Labs - TipRanks Mon, 09 Mar 2026 12
- Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs in $5.00 per Share Deal - GuruFocus Sat, 07 Mar 2026 00
- Breakout Move: Is LSTA stock good for income investors - 2026 Major Catalysts & Low Risk High Win Rate Stock Picks - baoquankhu1.vn Wed, 11 Mar 2026 02
- LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - Business Wire Wed, 21 Jan 2026 08
- Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq ue, 24 Feb 2026 08
- Lisata Therapeutics Enters Into Term Sheet to be Acquired - GlobeNewswire Wed, 21 Jan 2026 08
- Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga Mon, 09 Mar 2026 08
- Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva - The Globe and Mail hu, 22 Jan 2026 08
- Lisata Therapeutics (LSTA) extends Kuva Labs takeover term sheet deadline - Stock Titan Fri, 27 Feb 2026 08
- Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news Wed, 21 Jan 2026 08
- Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Wed, 21 Jan 2026 08
- Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Morningstar Wed, 28 Jan 2026 08
- Nasdaq Moves: Should I average down on LSTA stock - 2026 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn Sun, 08 Mar 2026 20
- Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - TipRanks Fri, 27 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 30456 | — | — | Stock Award(Grant) at price 0.00 per share. | HENSON HEIDI | Director | — | 2026-01-09 00:00:00 | D |
| 1 | 30456 | — | — | Stock Award(Grant) at price 0.00 per share. | BROWN GREGORY B | Director | — | 2026-01-09 00:00:00 | D |
| 2 | 30456 | — | — | Stock Award(Grant) at price 0.00 per share. | KLOSK STEVEN MARK | Director | — | 2026-01-09 00:00:00 | D |
| 3 | 30456 | — | — | Stock Award(Grant) at price 0.00 per share. | AZAB MOHAMMAD | Director | — | 2026-01-09 00:00:00 | D |
| 4 | 81000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAZZO DAVID J | Officer and Director | — | 2026-01-09 00:00:00 | D |
| 5 | 30456 | — | — | Stock Award(Grant) at price 0.00 per share. | FLOWERS CYNTHIA LOUISE | Director | — | 2026-01-09 00:00:00 | D |
| 6 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | BUCK KRISTEN K | Officer | — | 2026-01-09 00:00:00 | D |
| 7 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | NISCO JAMES | Officer | — | 2026-01-09 00:00:00 | D |
| 8 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | IMAM TARIQ | General Counsel | — | 2026-01-09 00:00:00 | D |
| 9 | 15789 | — | — | Stock Award(Grant) at price 0.00 per share. | HENSON HEIDI | Director | — | 2025-01-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 72.30K | 273.93K | 45.99K | 7.86K |
| TaxRateForCalcs | 0.04 | 0.10 | 0.04 | 0.05 |
| NormalizedEBITDA | -24.12M | -28.24M | -58.58M | -29.15M |
| TotalUnusualItems | 1.88M | 2.72M | 1.05M | 151.00K |
| TotalUnusualItemsExcludingGoodwill | 1.88M | 2.72M | 1.05M | 151.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.98M | -20.84M | -54.23M | -27.47M |
| ReconciledDepreciation | 174.00K | 189.00K | 69.00K | 55.00K |
| EBITDA | -22.23M | -25.52M | -57.53M | -29.00M |
| EBIT | -22.41M | -25.71M | -57.60M | -29.05M |
| NormalizedIncome | -21.80M | -23.29M | -55.23M | -27.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.98M | -20.84M | -54.23M | -27.47M |
| TotalExpenses | 23.41M | 25.71M | 57.60M | 29.05M |
| TotalOperatingIncomeAsReported | -22.41M | -25.71M | -57.60M | -29.05M |
| DilutedAverageShares | 8.33M | 8.07M | 5.18M | 3.69M |
| BasicAverageShares | 8.33M | 8.07M | 5.18M | 3.69M |
| DilutedEPS | -2.40 | -2.58 | -10.47 | -7.45 |
| BasicEPS | -2.40 | -2.58 | -10.47 | -7.45 |
| DilutedNIAvailtoComStockholders | -19.98M | -20.84M | -54.23M | -27.47M |
| NetIncomeCommonStockholders | -19.98M | -20.84M | -54.23M | -27.47M |
| NetIncome | -19.98M | -20.84M | -54.23M | -27.47M |
| MinorityInterests | 0.00 | 0.00 | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -19.98M | -20.84M | -54.23M | -27.47M |
| NetIncomeContinuousOperations | -19.98M | -20.84M | -54.23M | -27.47M |
| TaxProvision | -798.00K | -2.33M | -2.48M | -1.51M |
| PretaxIncome | -20.78M | -23.17M | -56.70M | -28.97M |
| OtherIncomeExpense | 1.63M | 2.54M | 897.00K | 76.00K |
| OtherNonOperatingIncomeExpenses | -257.00K | -186.00K | -155.00K | -75.00K |
| GainOnSaleOfSecurity | 1.88M | 2.72M | 1.05M | 151.00K |
| OperatingIncome | -22.41M | -25.71M | -57.60M | -29.05M |
| OperatingExpense | 23.41M | 25.71M | 57.60M | 29.05M |
| ResearchAndDevelopment | 11.33M | 12.73M | 43.46M | 17.58M |
| SellingGeneralAndAdministration | 12.07M | 12.97M | 14.14M | 11.47M |
| GeneralAndAdministrativeExpense | 12.07M | 12.97M | 14.14M | 11.47M |
| OtherGandA | 12.07M | 12.97M | 14.14M | 11.47M |
| TotalRevenue | 1.00M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 1.00M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 738.00 | 738.00 | 738.00 | 738.00 |
| OrdinarySharesNumber | 8.41M | 8.15M | 7.90M | 3.99M |
| ShareIssued | 8.41M | 8.15M | 7.90M | 3.99M |
| TotalDebt | 137.00K | 168.00K | 180.00K | 714.00K |
| TangibleBookValue | 29.38M | 47.88M | 66.24M | 92.25M |
| InvestedCapital | 29.57M | 48.15M | 66.58M | 92.25M |
| WorkingCapital | 28.96M | 47.33M | 65.49M | 91.66M |
| NetTangibleAssets | 29.38M | 47.88M | 66.24M | 92.25M |
| CapitalLeaseObligations | 137.00K | 168.00K | 180.00K | 714.00K |
| CommonStockEquity | 29.57M | 48.15M | 66.58M | 92.25M |
| TotalCapitalization | 29.57M | 48.15M | 66.58M | 92.25M |
| TotalEquityGrossMinorityInterest | 29.32M | 47.89M | 66.32M | 92.00M |
| MinorityInterest | -254.00K | -254.00K | -254.00K | -254.00K |
| StockholdersEquity | 29.57M | 48.15M | 66.58M | 92.25M |
| GainsLossesNotAffectingRetainedEarnings | -81.00K | -42.00K | -29.00K | -70.00K |
| OtherEquityAdjustments | -81.00K | -42.00K | -29.00K | -70.00K |
| TreasuryStock | 708.00K | 708.00K | 708.00K | 708.00K |
| RetainedEarnings | -548.07M | -528.08M | -507.24M | -453.02M |
| AdditionalPaidInCapital | 578.42M | 576.97M | 574.55M | 546.04M |
| CapitalStock | 8.00K | 8.00K | 8.00K | 4.00K |
| CommonStock | 8.00K | 8.00K | 8.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 5.68M | 6.80M | 6.71M | 5.01M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 72.00K | 210.00K | 327.00K | 485.00K |
| OtherNonCurrentLiabilities | 72.00K | 210.00K | 327.00K | |
| LongTermDebtAndCapitalLeaseObligation | 305.00K | 485.00K | ||
| LongTermCapitalLeaseObligation | 305.00K | 485.00K | ||
| CurrentLiabilities | 5.61M | 6.59M | 6.38M | 4.52M |
| CurrentDebtAndCapitalLeaseObligation | 137.00K | 168.00K | 180.00K | 229.00K |
| CurrentCapitalLeaseObligation | 137.00K | 168.00K | 180.00K | 229.00K |
| PayablesAndAccruedExpenses | 5.48M | 6.42M | 6.20M | 4.29M |
| CurrentAccruedExpenses | 4.19M | 4.00M | 3.55M | 2.36M |
| Payables | 1.28M | 2.42M | 2.65M | 1.93M |
| AccountsPayable | 1.28M | 2.42M | 2.65M | 1.93M |
| TotalAssets | 35.00M | 54.69M | 73.03M | 97.01M |
| TotalNonCurrentAssets | 424.00K | 770.00K | 1.16M | 826.00K |
| OtherNonCurrentAssets | 160.00K | 332.00K | 528.00K | 764.00K |
| GoodwillAndOtherIntangibleAssets | 192.00K | 263.00K | 334.00K | 0.00 |
| OtherIntangibleAssets | 192.00K | 263.00K | 334.00K | |
| NetPPE | 72.00K | 175.00K | 296.00K | 62.00K |
| AccumulatedDepreciation | -589.00K | -486.00K | -417.00K | -368.00K |
| GrossPPE | 661.00K | 661.00K | 713.00K | 430.00K |
| Leases | 72.00K | 72.00K | 99.00K | 90.00K |
| MachineryFurnitureEquipment | 589.00K | 589.00K | 614.00K | 340.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 34.58M | 53.92M | 71.88M | 96.18M |
| OtherCurrentAssets | 2.43M | 3.39M | 2.65M | 1.21M |
| PrepaidAssets | 1.21M | |||
| Receivables | 900.00K | 0.00 | ||
| AccountsReceivable | 900.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 31.25M | 50.53M | 69.23M | 94.97M |
| OtherShortTermInvestments | 15.04M | 27.94M | 37.07M | 70.32M |
| CashAndCashEquivalents | 16.21M | 22.59M | 32.15M | 24.65M |
| CashEquivalents | 16.71M | 27.67M | ||
| CashFinancial | 5.88M | 4.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.36M | -20.03M | -21.45M | -22.30M |
| IssuanceOfCapitalStock | 68.00K | 321.00K | 43.00K | 85.50M |
| CapitalExpenditure | -285.00K | -60.00K | ||
| InterestPaidSupplementalData | 0.00 | |||
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 16.21M | 22.59M | 32.15M | 24.65M |
| BeginningCashPosition | 22.59M | 32.15M | 24.65M | 16.51M |
| EffectOfExchangeRateChanges | -55.00K | -16.00K | -10.00K | 0.00 |
| ChangesInCash | -6.33M | -9.54M | 7.52M | 8.13M |
| FinancingCashFlow | -206.00K | 385.00K | -224.00K | 85.28M |
| CashFlowFromContinuingFinancingActivities | -206.00K | 385.00K | -224.00K | 85.28M |
| NetOtherFinancingCharges | -274.00K | -91.00K | -267.00K | -248.00K |
| ProceedsFromStockOptionExercised | 0.00 | 155.00K | 0.00 | 24.00K |
| NetCommonStockIssuance | 68.00K | 321.00K | 43.00K | 85.50M |
| CommonStockIssuance | 68.00K | 321.00K | 43.00K | 85.50M |
| InvestingCashFlow | 13.23M | 10.10M | 28.91M | -54.90M |
| CashFlowFromContinuingInvestingActivities | 13.23M | 10.10M | 28.91M | -54.90M |
| NetOtherInvestingChanges | -3.32M | |||
| NetInvestmentPurchaseAndSale | 13.36M | 10.10M | 32.52M | -54.84M |
| SaleOfInvestment | 69.05M | 108.58M | 122.20M | 124.94M |
| PurchaseOfInvestment | -55.69M | -98.48M | -89.69M | -179.78M |
| NetBusinessPurchaseAndSale | -130.00K | 0.00 | ||
| PurchaseOfBusiness | -130.00K | 0.00 | ||
| NetPPEPurchaseAndSale | 0.00 | -285.00K | -60.00K | |
| PurchaseOfPPE | 0.00 | -285.00K | -60.00K | |
| OperatingCashFlow | -19.36M | -20.03M | -21.17M | -22.25M |
| CashFlowFromContinuingOperatingActivities | -19.36M | -20.03M | -21.17M | -22.25M |
| ChangeInWorkingCapital | -873.00K | -462.00K | -831.00K | 647.00K |
| ChangeInOtherCurrentAssets | 170.00K | 274.00K | 237.00K | -150.00K |
| ChangeInPayablesAndAccruedExpense | -995.00K | 88.00K | -223.00K | 1.25M |
| ChangeInPayable | -995.00K | 88.00K | ||
| ChangeInAccountPayable | -995.00K | 88.00K | ||
| ChangeInPrepaidAssets | 852.00K | -824.00K | -845.00K | -453.00K |
| ChangeInReceivables | -900.00K | 0.00 | ||
| ChangesInAccountReceivables | -900.00K | 0.00 | ||
| OtherNonCashItems | 30.39M | |||
| StockBasedCompensation | 1.65M | 2.04M | 2.64M | 2.00M |
| AmortizationOfSecurities | -455.00K | -960.00K | 788.00K | 2.51M |
| DepreciationAmortizationDepletion | 174.00K | 189.00K | 69.00K | 55.00K |
| DepreciationAndAmortization | 174.00K | 189.00K | 69.00K | 55.00K |
| OperatingGainsLosses | 130.00K | 3.00K | ||
| EarningsLossesFromEquityInvestments | 130.00K | 0.00 | ||
| GainLossOnSaleOfPPE | 0.00 | 3.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -19.98M | -20.84M | -54.23M | -27.47M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LSTA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|